Introduction {#sec1}
============

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a common method for evaluating tumor response to therapy in a variety of cancers ([@B1]--[@B3]), including breast ([@B4], [@B5]). DCE-MRI acquires images before, during, and after injection of a contrast agent to characterize, for example, tumor-related perfusion. To perform a quantitative analysis of DCE-MRI data, knowledge of the precontrast longitudinal relaxation time (*T*~1~) is required to convert the measured dynamic signal intensity into a time course of the concentration of the contrast agent ([@B6]). A popular technique used to measure the precontrast *T*~1~ is the variable flip angle (VFA) approach, which uses a series of spoiled gradient echo (SPGE) images acquired with a short, fixed repetition time (TR) and a varying flip angle ([@B7], [@B8]). The resulting data are then fit to the signal intensity equation describing the SPGE acquisition with *T*~1~ as a fit parameter for each voxel or region of interest (ROI). Although this technique allows for rapid 3-dimensional (3D) *T*~1~ mapping, it is not without limitations, chief of which is that its accuracy is dependent on the uniformity of the transmit radiofrequency (*B*~1~) field. It should be noted that other *T*~1~ mapping methods exist that are less sensitive to variations in the transmit field ([@B9]); however, VFA sequences are the preferred method in the clinical setting, as these acquisitions enable a large field of view (FOV) to be measured in a relatively short period.

Inhomogeneities in the *B*~1~ field cause variations in the prescribed flip angles, leading to inaccurate measurements of *T*~1~, which can subsequently induce large errors in the DCE-MRI parameters (eg, the volume transfer rate constant, *K^trans^*) ([@B10]). Indeed, simulation results indicated that errors in *K^trans^* ranged from 15% to 500% as the error in the *T*~1~ measurement ranged from 14% to 65% of the nominal value ([@B11]). Therefore, an inaccurate estimation of the precontrast *T*~1~ could potentially lower the sensitivity of DCE-MRI for characterizing tumor vascular properties, thereby limiting the utility of the technique.

The *B*~1~ field experienced by spins within the body is influenced by several factors, including the distance of the spins from the radiofrequency transmit coil, the dielectric properties of the tissues, and the factors related to body size and wavelength of the radiofrequency ([@B12]). The severity of the nonuniformity in the *B*~1~ field increases at higher field strengths ([@B13]), and noticeable *B*~1~ inhomogeneities have been observed in the breast at 3 T ([@B14]--[@B17]). In particular, a substantial variation in the *B*~1~ field from left to right across the imaging FOV has been observed, which may artificially decrease the contrast enhancement in specific lesions ([@B18]). Thus, Kuhl et al. have suggested that *B*~1~ mapping in the breast should be a standard practice ([@B14]). Although several different methods for *B*~1~ mapping have been developed ([@B12], [@B19]--[@B22]), no single method has emerged for widespread application.

A technique using the Bloch--Siegert shift to map the *B*~1~ field has recently been developed, and it is an area of active investigation ([@B23]--[@B26]). The Bloch--Siegert shift is a term used to describe the shift in resonance frequency of a nucleus when an off-resonance radiofrequency field is applied ([@B27]). Although Sacolick et al. ([@B24]) provide the details, the salient information is mentioned here. If a radiofrequency pulse is applied either far enough off-resonance and/or with a pulse shape such that it does not cause spin excitation, the spins experience a change in precession frequency without excitation ([@B28]). The spin precession frequency shifts away from the off-resonance irradiation and is dependent on the magnitude of the *B*~1~ field, as well as the difference between the spin resonance frequency and radiofrequency field. The shift in frequency results in a phase shift in the images that can be used to spatially map the *B*~1~ magnitude. This phase-based method generates a *B*~1~ map that is not significantly biased by TR, *T*~1~ relaxation, flip angle, chemical shift, background field inhomogeneity, or magnetization transfer ([@B24]). The insensitivity to TR is especially important in a clinical setting, as it allows for the prompt acquisition of image data with a short TR. In the current study, we present an approach to rapidly, accurately, and precisely map *B*~1~ and *T*~1~ values in the breast using the Bloch--Siegert method with a VFA sequence.

Methodology {#sec2}
===========

All imaging data were acquired with a 3 T Achieva magnetic resonance scanner (Philips Healthcare, Best, The Netherlands) equipped with a 2-channel multitransmit body coil and a MammoTrak table including a 16-channel receive double-breast coil (Philips Healthcare, Best, The Netherlands).

Phantom Scans {#sec2-1}
-------------

To investigate the feasibility of the approach, 8 gel phantoms (The Eurospin II Test System, Diagnostic Sonar, Livingston, Scotland, UK) submerged in water were scanned at room temperature. The *T*~1~ values of the phantoms ranged from 300 to 1600 milliseconds. A coronal image volume was placed in the center of the breast coil containing the phantoms, and VFA, Bloch--Siegert, and inversion recovery (IR) data were collected. VFA data with 10 flip angles (2, 4, 6, . . . 20) were acquired using a 3D SPGE sequence with the following parameters: TR/echo time (TE) = 7.9/4.6 milliseconds, sensitivity encoding parallel imaging factor of 2, acquisition matrix of 192 × 192 over a FOV of 256 × 256 mm^2^, yielding a voxel size of 1.33 × 1.33 mm^2^, and 15 slices with a thickness of 4 mm for a total scan time of 66 seconds. The Bloch--Siegert data were collected using a gradient echo sequence with a 2-millisecond frequency-swept *B*~1~ phase imparting pulse ([@B25]) over the same FOV as the VFA data with the following parameters: TR/TE = 491/5.4 millisecond, acquisition matrix of 104 × 102, reconstruction voxel size of 1.33 × 1.33 mm^2^, and root mean square *B*~1~ field = 2.29 μT for a total scan time of 104 seconds. As is required with the Bloch--Siegert *B*~1~ mapping, 2 images were collected at opposite frequency offsets. As a gold standard, a 2-dimensional IR-prepared turbo-spin echo (IR-TSE) sequence was used to acquire a single slice corresponding to the center of the VFA image volume with the following parameters: 12 inversion times of 25, 50, 75, 100, 200, 300, 400, 500, 1000, 2000, 4000, and 10 000 milliseconds, acquisition matrix of 128 × 96 over an FOV of 256 × 256 mm^2^, reconstruction voxel size of 1.33 × 1.33 mm^2^, predelay before inversion pulse of 2500 milliseconds, and TSE factor of 24 with an echo spacing of 5.9 milliseconds for a total scan time of 125 seconds.

Subject Scans {#sec2-2}
-------------

Test--retest MRI sessions were performed on 16 women (median: 42 years, range: 25--67) with no history of breast disease. Because of age, body habitus, or hormonal status, 4 of these women did not have appreciable fibroglandular tissue (FGT) in either breast; thus, measurements for these women included data only from the adipose tissue (AT). The imaging protocol consisted of 2 scan sessions each lasting ∼30 minutes separated by a 10-minute rest period. During the rest period, the subjects were removed from the scanner and allowed to stretch. All subjects were consented as part of an ongoing study approved by the local Institutional Review Board.

For each test--retest session, 2 separate sagittal imaging volumes were centered on each breast with an attempt to approximately match the stack placement between each imaging session. Subsequent VFA, Bloch--Siegert, and IR data were then collected separately for each breast. The imaging parameters for each sequence were identical to the phantom scans, except that the slice thickness was 5 mm and the number of slices for the VFA and Bloch--Siegert sequences was 10. These 2 parameters were changed to match our ongoing clinical imaging trial ([@B29]). In addition, we applied the *T*~1~ and Bloch--Siegert *B*~1~ mapping methods described herein on 3 patients with breast cancer. Each patient provided written consent to participate in the study.

Image Analysis {#sec2-3}
--------------

All image data were exported to MATLAB R2013b (The MathWorks, Natick, Massachusetts) for analysis. Bloch--Siegert *B*~1~ maps were calculated as described previously ([@B25]). In brief, the actual flip angle at each image voxel was obtained via linear interpolation of the entries of a phase difference-versus-*B*~1~ strength lookup table generated using Bloch equation simulations of the off-resonant Bloch--Siegert pulse. The flip angle correction map was then calculated as the ratio of the actual flip angle to the prescribed flip angle.

VFA *T*~1~ maps with and without *B*~1~ correction were obtained by fitting signal intensity (*S*) data to equation 1 as follows: $$S = S_{0} \cdot \frac{\left. \sin(f \cdot \alpha) \cdot (1 - \exp( - TR/T_{1}) \right.}{\left. 1 - (\exp( - TR/T_{1}) \cdot \cos(f \cdot \alpha)) \right.}$$ where *S*~0~ is a constant related to scanner gain and proton density, α is the prescribed flip angle, and *f* is the Bloch--Siegert-derived flip angle correction factor (set to 1 for the uncorrected *T*~1~ map), and we have taken TE ≪ *T*~2~\*. In addition, *T*~1~ maps were calculated by fitting the IR-TSE data ([@B30]) to equation 2 as follows: $$\left. S = S_{0} \cdot \middle| (\cos\alpha \cdot (1 - \exp( - TD/T_{1})) \cdot \exp( - TI/T_{1})) + 1 - \exp( - TI/T_{1}) \middle| \cdot \,\,\, \right.$$

For the phantom scans, circular ROIs were manually drawn within each gel phantom using the IR data as a guide. The average *T*~1~ from each phantom was recorded from the IR *T*~1~ map. The same ROIs were then subsequently used to calculate the average *T*~1~ from the central slice of the VFA-derived *T*~1~ maps with and without *B*~1~ correction. Statistical analyses were performed on the average *T*~1~ values calculated from each ROI. To evaluate the accuracy of the proposed *B*~1~ mapping technique, the percent error (%err) between the IR- and VFA-derived *T*~1~ values (with and without *B*~1~ correction) was calculated.

For healthy volunteers, segmentation masks for AT were automatically generated from the IR data (inversion times = 500 milliseconds), where the signal intensity for the FGT was close to 0. A representative example of the segmentation masks for each tissue is presented in [Supplemental Figure 3](#SD3){ref-type="supplementary-material"}. FGT segmentation masks were subsequently generated as the opposite of the AT mask after manually segmenting the skin and chest wall from the FOV. The average *T*~1~ from each tissue segmentation mask was recorded from the IR *T*~1~ maps for each breast and imaging session. The same tissue masks were then used to calculate the average *T*~1~ from the central slice of the VFA-derived *T*~1~ maps (with and without *B*~1~ correction). The %err between the VFA-derived *T*~1~ values (with and without *B*~1~ correction) and the IR *T*~1~ values was calculated to evaluate the accuracy, and the agreement between the different *T*~1~ values was assessed via the concordance correlation coefficient (CCC). Furthermore, the bootstrap 95% confidence interval (CI) of the mean differences in absolute deviation between IR- and VFA-derived *T*~1~ values (with and without *B*~1~ correction) was computed as previously described ([@B31]) using equation 3 as follows: $$\left. avg_{i} = \text{average}( \middle| VFA\text{-}IR\text{|-|}VFA_{B_{1}}\text{-}IR \right|)$$ where *VFA* and *VFA*~*B*~1~~ are VFA-derived *T*~1~ values without and with *B*~1~ correction, respectively. Equation 3 is first computed with all *T*~1~ values (ie, 2 scan sessions per subject equals 32 and 26 *T*~1~ values for AT and FGT, respectively, in each breast). Next, the *n* × *m* matrix of data is randomly resampled with replacement from the original data set (such that data from a subject(s) could be included more than once) and then equation 3 is recomputed. In the AT case, for example, the *m* × *n* matrix size is 16 × 2, as there are 16 patients with 2 data points each. This process is repeated 1000 times, generating a new matrix of *m* × *n* data points, which are then used to calculate the upper and lower bounds of the bootstrap 95% CIs. The number of data points *n* is the total number of subjects.

To illustrate the application of the *T*~1~ and *B*~1~ mapping techniques described herein, manual ROIs were drawn in the AT, FGT (if appreciable), and tumor of 3 patients with breast cancer. Average *T*~1~ from each ROI was calculated, and the %err between the VFA-derived *T*~1~ values (with and without *B*~1~ correction) and the IR *T*~1~ values was compared.

Reproducibility Statistics {#sec2-4}
--------------------------

Reproducibility statistics used in this test--retest study follow the methods previously described by Bland and Altman ([@B32]) and are similar to what was previously implemented in the breast of healthy volunteers ([@B33], [@B34]). First, the difference, *d*, was calculated between the 2 VFA *T*~1~ data sets obtained for each subject and then the distribution of those differences was tested for normality using the Shapiro--Wilk test. The Kendall\'s Tau test was used to ensure that the magnitude of the difference values was not correlated with the parameter mean of the repeated measurements. The Wilcoxon signed-rank test was used to test the null hypothesis of no bias (ie, average difference is 0) between repeated measurements.

The statistical measurements of reproducibility were calculated as follows: (1) The root-mean-square deviation (*rMSD*) is computed using the differences, *d*, as follows: $${r\text{MSD} = \sqrt{\frac{\sum d^{2}}{n}}}.$$(2) The 95% CI for a group of *n* subjects is shown as follows: $$\text{CI}\, = \, \pm \frac{1.96 \cdot \text{std}(d)}{\sqrt{n}}$$ where std(*d*) is the standard deviation of *d*. The confidence interval indicates the range of expected measurement variability in a group of *n* subjects.(3) The within-subject standard deviation (*wSD*) is as follows: $$\text{wSD} = \frac{\text{rMSD}}{\sqrt{2}}$$(4) The repeatability coefficient (*r*) is shown as follows: $$\text{r = 2.77} \cdot \text{wSD}$$

Or, equivalently, as follows: $$\text{r = 1.96} \cdot \text{rMSD}$$

The repeatability coefficient defines the magnitude of the maximum difference expected in 95% of paired observations; for example, *r* defines the expected measurement variability for an individual. Because of our moderate sample sizes, we replaced 1.96 in equation 5 with the appropriate *t*-statistic for our sample size, which was 2.131 (n = 16) and 2.179 (n = 13) for AT and FGT, respectively.

Statistical analyses were performed using the statistical toolbox in MATLAB^®^. A significance value of *P* ≤ .05 was used for all statistical tests. In addition, we quantified the coefficient of variation (CV) between the repeated measurements, which is the ratio of the standard deviation of the repeated measurements over the mean of the repeated measurements.

Results {#sec3}
=======

Gel Phantoms {#sec3-1}
------------

A set of image data for the gel phantom experiment is displayed in [Figure 1](#F1){ref-type="fig"}. The Bloch--Siegert *B*~1~ map is displayed in [Figure 1A](#F1){ref-type="fig"}, where each voxel represents the Bloch--Siegert-derived flip angle correction factor (ie, ratio of the actual flip angle to the nominal flip angle) that is incorporated into equation 1. *T*~1~ parametric maps generated from the IR, uncorrected VFA, and *B*~1~-corrected VFA data are displayed in panels B, C, and D, respectively, of [Figure 1](#F1){ref-type="fig"}. The mean (±standard deviation) *T*~1~ value for each gel phantom ROI, along with the %err from the IR data, is listed in [Table 1](#T1){ref-type="table"}. Compared with the uncorrected VFA data, the *B*~1~-corrected VFA-derived *T*~1~ estimates have a significantly lower %err (*P* = .016, Wilcoxon signed-rank).

![A Bloch--Siegert *B*~1~ map (A) with *T*~1~ parametric maps calculated from inversion recovery (IR) (B) and uncorrected variable flip angle (VFA) (C), and *B*~1~-corrected VFA data (D) are shown for the gel phantoms. The Bloch--Siegert *B*~1~ map shown is the correction factor, which is the ratio of the actual and nominal flip angles. Note the large spatial variation across the *B*~1~ map; this variation is a representation of the *B*~1~ inhomogeneity across the imaging field of view (FOV). After *B*~1~ correction, the VFA-derived *T*~1~ values (D) are more similar to the IR *T*~1~ values (B) in each gel phantom.](tom2221600410001){#F1}

###### 

Average ± Standard *T*~1~ (milliseconds) Values and %err in the Gel Phantoms

   Tube No.  IR          VFA w/o *B*~1~   %err   VFA w/*B*~1~    %err
  ---------- ----------- ---------------- ------ -------------- ------
      1      322 ± 25    364 ± 14         13     319 ± 8          1
      2      328 ± 37    401 ± 10         22     331 ± 9          1
      3      835 ± 37    889 ± 39         7      816 ± 20         2
      4      843 ± 39    963 ± 40         14     822 ± 22         3
      5      1004 ± 51   1160 ± 21        15     940 ± 43         6
      6      1478 ± 54   1573 ± 59        6      1357 ± 56        8
      7      1500 ± 19   1412 ± 64        6      1454 ± 87        3
      8      1558 ± 22   1727 ± 62        8      1558 ± 50        3

Abbreviations: No., number; %err, percent error; IR, inversion recovery; VFA, variable flip angle.

In Vivo Scans {#sec3-2}
-------------

A representative set of image data is displayed for the right breast of 1 subject in [Figure 2](#F2){ref-type="fig"}. (Identical data for the left breast in the same subject are displayed in [Supplemental Figure 1](#SD1){ref-type="supplementary-material"}.) The Bloch--Siegert *B*~1~ maps from both scans are displayed in [Figure 2, A](#F2){ref-type="fig"} and [E](#F2){ref-type="fig"}, where each voxel displays the Bloch--Siegert-derived flip angle correction factor. Also shown, are test--retest *T*~1~ parametric maps generated from the IR (panels B and F), uncorrected VFA (panels C and G), and *B*~1~-corrected VFA (panels D and H) data. Average *T*~1~ values from each tissue ROI and *T*~1~ mapping technique are tabulated for the right and left breast from each subject in [Supplemental Tables 1](#SD4){ref-type="supplementary-material"} and [2](#SD5){ref-type="supplementary-material"}, respectively.

![A representative test--retest set of *B*~1~ and *T*~1~ parametric maps displayed for the right breast of a healthy volunteer. Bloch--Siegert *B*~1~ maps (A and E) correspond to the correction between the actual and the nominal flip angles. Note the spatial variation of the correction factors in the *B*~1~ maps and the difference in *B*~1~ maps between repeated scans; together, these images provide evidence that a *B*~1~ map should be incorporated into routine breast imaging if a quantitative analysis of the collected data is desired. *T*~1~ parametric maps include: IR maps (B and F), uncorrected VFA maps (C and G), and *B*~1~-corrected VFA maps (D and H). The spatial variations in *T*~1~ of the FGT are minimized after *B*~1~ correction, and the *T*~1~ map more closely matches the IR *T*~1~ map. Furthermore, the *B*~1~-corrected *T*~1~ maps are visually more similar between repeated measurements compared with the uncorrected data. Observe how the orientation is slightly different between repeated scans, which might negatively affect the *T*~1~ reproducibility, as the same tissue sections from each scan might not be analyzed.](tom2221600410002){#F2}

[Table 2](#T2){ref-type="table"} lists the accuracy results for each ROI and breast. In the right breast, %err in the FGT using the VFA method significantly (*P* \< .001, Wilcoxon signed-rank) decreased from 17.0% to 8.6% and the CCC increased from 0.55 to 0.83 after *B*~1~ correction. Similar trends in accuracy were observed in the AT ([Table 2](#T2){ref-type="table"}). Bootstrap 95% CIs for FGT and AT were 57.8--139 milliseconds and 17.2--42.2 milliseconds, respectively. The range of CIs for each tissue includes all positive numbers, and by referring to equation 3, it can be seen that the absolute difference from the gold standard IR *T*~1~ is smaller after *B*~1~ correction for both tissue ROIs. In the left breast, %err in the FGT using the VFA method significantly (*P* = .002, Wilcoxon signed-rank) decreased from 15.0% to 8.7% and the CCC increased from 0.60 to 0.83 after *B*~1~ correction. Similar trends in accuracy were observed in the AT ([Table 2](#T2){ref-type="table"}). The bootstrap 95% CIs for FGT and AT were 35.8--104.8 milliseconds and 2.4--26.7 milliseconds, respectively; again, both values for each CI were positive, indicating that the absolute difference from gold standard IR *T*~1~ is smaller after *B*~1~ correction for both ROIs.

###### 

Accuracy Results for Both Breasts and ROI

                              Right Breast   Left Breast                 
  --------------------------- -------------- ------------- ------------- ------
  **Adipose Tissue**                                                     
  VFA                         13% (9.7%)     0.26          13% (11%)     0.29
  VFA w/*B*~1~                6.2% (4.8%)    0.59          9.4% (7.3%)   0.5
  **Fibroglandular Tissue**                                              
  VFA                         17% (9.1%)     0.55          15% (11%)     0.6
  VFA w/*B*~1~                8.6% (7.4%)    0.83          8.7% (5.5%)   0.83

Abbreviations: ROI, region of interest; %err, percent error; Std, standard deviation; CCC, concordance correlation coefficient; VFA, variable flip angle.

As a proof of principle, the *T*~1~ and *B*~1~ mapping methods were applied in 3 patients with breast cancer. [Figure 3](#F3){ref-type="fig"} displays *T*~1~ parametric maps for all 3 patients generated from IR (left column), uncorrected VFA (center column), and *B*~1~-corrected VFA (right column) data. From these images, it can be seen that the *B*~1~-corrected *T*~1~ values in the tumors more closely match the IR *T*~1~ values. This similarity is extremely important, as accurate *T*~1~ values are required when performing a quantitative DCE-MRI analysis. The mean (±standard deviation) *T*~1~ value for each tissue ROI, along with the %err from the IR data, is listed in [Table 3](#T3){ref-type="table"} for each patient with breast cancer. Compared with the uncorrected VFA data, the *B*~1~-corrected VFA-derived *T*~1~ estimates have, on average, a lower %err. Combining all tissue ROIs for each imaging technique, a significantly lower %err was observed after *B*~1~ correction (*P* = .004, Wilcoxon signed-rank).

![As a proof of principle, the *B*~1~ and *T*~1~ methods presented in this article were performed on 3 patients with breast cancer; each patient was a subject enrolled in our ongoing breast imaging clinical trial ([@B29]). *T*~1~ parametric maps are shown for IR (left center column), uncorrected VFA (right center column), and *B*~1~-corrected VFA (right column) data collected from each patient (shown in rows). The tumors are shown with red arrows in each image. Compared with the uncorrected VFA data, the *B*~1~-corrected VFA *T*~1~ values of the FGT, AT, and tumor in all 3 patients are more similar to the IR *T*~1~ values, thus suggesting a more accurate *T*~1~ value in each tissue after *B*~1~ correction. Note that circular regions in the breasts that have a lack of signal intensity are due to the presence of a breast biopsy clip.](tom2221600410003){#F3}

###### 

Average ± Standard *T*~1~ (milliseconds) Values and %err from ROIs in Patients with Breast Cancer

   Patient  ROI          IR           VFA w/o *B*~1~   %err         VFA w/*B*~1~   %err
  --------- ------------ ------------ ---------------- ------------ -------------- ------
      1     Tumor        1364 ± 292   1682 ± 330       23           1514 ± 269     11
     AT     411 ± 10     470 ± 48     14               384 ± 36     7              
     FGT    1391 ± 336   1807 ± 215   30               1383 ± 164   1              
      2     Tumor        1374 ± 376   2104 ± 267       53           1721 ± 209     25
     AT     397 ± 10     439 ± 34     11               409 ± 33     3              
     FGT    1493 ± 224   1725 ± 99    16               1578 ± 79    6              
      3     Tumor        1101 ± 345   1275 ± 381       16           1151 ± 344     5
     AT     407 ± 7      465 ± 45     14               415 ± 41     2              
     FGT    1471 ± 319   2036 ± 343   38               1594 ± 271   8              

Abbreviations: ROI, region of interest; %err, percent error; IR, inversion recovery; VFA, variable flip angle; AT, adipose tissue; FGT, fibroglandular tissue.

Reproducibility {#sec3-3}
---------------

Reproducibility statistics for each tissue are listed in [Table 4](#T4){ref-type="table"} and [Supplemental Table 3](#SD6){ref-type="supplementary-material"} for the right and left breast, respectively. Normality was assumed for each data set as determined by the Shapiro--Wilk test. No data sets had an average difference significantly different from 0 as determined by the Wilcoxon signed-rank test. In addition, the Kendall\'s Tau test showed that the difference between repeat measurements *d* was independent of the mean for each ROI.

###### 

Reproducibility Results for the Right Breast

                              Mean   Mean Difference   95% CI for Mean Difference   wSD   Repeatability   CV (Mean ± SD)
  --------------------------- ------ ----------------- ---------------------------- ----- --------------- ----------------
  **Adipose Tissue**                                                                                      
  VFA                         429    40                ±28 (6.5%)                   38    104             6.7% ± 6.1%
  VFA w/*B*~1~                418    19                ±14 (3.3%)                   18    48              3.2% ± 3.0%
  **Fibroglandular Tissue**                                                                               
  VFA                         1316   106               ±94 (7.1%)                   100   276             4.7% ± 4.9%
  VFA w/*B*~1~                1256   49                ±38 (3.0%)                   40    111             2.6% ± 1.5%

Abbreviations: CI, confidence interval; wSD, within-subject standard deviation; CV, coefficient of variation; SD, standard deviation; VFA, variable flip angle.

Bland--Altman plots for each tissue ROI are displayed in [Figure 4](#F4){ref-type="fig"} and [Supplemental Figure 2](#SD2){ref-type="supplementary-material"} for the right and left breast, respectively. Each panel displays the difference in *T*~1~ between the repeated scans against the mean *T*~1~ from both scans. The mean difference and 95% CIs of the mean difference are displayed as black and blue lines, respectively. The 95% CIs of the mean difference, which define expected measurement variability for a cohort of subjects, decreased after *B*~1~ correction. For the right breast, the 95% CI of the mean difference of the AT ROI decreased from ±28 milliseconds (6.5%) to ±14 milliseconds (3.3%) after *B*~1~ correction, whereas the 95% CI of the mean difference for the FGT ROI decreased from ±94 milliseconds (7.1%) to ±38 milliseconds (3.0%). The repeatability coefficient (red lines in [Figure 4](#F4){ref-type="fig"} and [Supplemental Figure 2](#SD2){ref-type="supplementary-material"}), which defines the measurement variability in an individual, decreased from 104 to 48 milliseconds in AT and from 276 to 111 milliseconds in FGT after *B*~1~ correction. Similar trends in the 95% CI of the mean difference and *r* were observed for both tissues in the left breast ([Supplemental Table 3](#SD6){ref-type="supplementary-material"}).

![Bland--Altman plots for the right breast displaying the difference in *T*~1~ between repeated measurements plotted against mean *T*~1~ for AT before *B*~1~ correction (A), AT after *B*~1~ correction (B), FGT before *B*~1~ correction (C), and FGT after *B*~1~ correction (D). The mean difference (black line) is shown with 95% confidence intervals of the mean difference (blue lines), which defines a measure of the spontaneous variability that is expected in a cohort of subjects. Repeatability is also shown (red lines), which quantifies the maximum difference expected to be observed between 2 repeat measurements in an individual. It can be noted from the figure that the width of both the 95% CIs of the mean difference and repeatability coefficient decreases after *B*~1~ correction, suggesting a lower variability.](tom2221600410004){#F4}

In the right breast, the CV ([Table 4](#T4){ref-type="table"}) significantly (*P* = .039, Wilcoxon signed-rank) decreased from 6.7% to 3.2% in the AT after *B*~1~ correction. In the FGT, the CV decreased from 5.5% to 2.2% after *B*~1~ correction; however, the difference was not statistically significant (*P* = .064). In the left breast ([Supplemental Table 3](#SD6){ref-type="supplementary-material"}), the CV significantly decreased from 7.5% to 3.9% in the AT (*P* = .002) and 6.8% to 2.4% in the FGT (*P* = .016) after *B*~1~ correction.

Discussion {#sec4}
==========

It is well known that variations in the *B*~1~ transmit field exist in the breast at 3 T ([@B14], [@B35]). Thus, applying a *B*~1~ correction scheme is critical---especially when measuring *T*~1~ with an acquisition technique that requires multiple flip angles (ie, the VFA technique). Any bias in the prescribed flip angle will lead to inaccuracies in the measured *T*~1~. The observed *T*~1~ values in the AT and FGT in this study are not unreasonable and are similar to a recent study by Bedair et al. that investigated the effect of a Bloch--Siegert *B*~1~ correction technique on VFA-derived measurements of *T*~1~ in the breast at 3 T ([@B36]). In addition, our study incorporated a comparison with the gold standard IR data and a reproducibility analysis, allowing for an evaluation of accuracy and precision of the combination of the Bloch--Siegert *B*~1~ and the VFA *T*~1~ mapping techniques. We showed that the *T*~1~ and *B*~1~ mapping methods described herein are not only appropriate for clinical applications but also produce accurate estimates of *T*~1~ in breast tissues, including FGT, AT, and breast cancer.

The feasibility of the presented *T*~1~ and *B*~1~ mapping techniques was shown in the gel phantom experiment. After *B*~1~ correction, the VFA-derived *T*~1~ values in each gel phantom more closely matched the gold standard IR *T*~1~ values, which was supported by the significantly lower %err (*P* = .016, Wilcoxon signed-rank). In addition, we observed that the Bloch--Siegert *B*~1~ mapping technique improved the accuracy of the VFA-derived *T*~1~ measurements in the breast. The %err in both ROIs (ie, FGT and AT) decreased after *B*~1~ correction for both breasts, suggesting that a smaller difference exists between the *B*~1~-corrected VFA and IR *T*~1~ values as compared to the uncorrected VFA data. The bootstrap 95% CIs were positive for all ROIs (including both breasts), indicating that the *T*~1~ values after *B*~1~ correction are more similar to the IR *T*~1~ data. Furthermore, the CCC increased by ∼50% for all measurements after *B*~1~ correction. Although the CCC value in the AT ROIs increased after *B*~1~ correction, the level of agreement after *B*~1~ correction was minimal (ie, CCC = ∼0.5) and much lower than the CCCs in the FGT. The radiofrequency pulses for the Bloch--Siegert technique described in this study were designed to produce pure phase shifts over a ±600 Hz range ([@B25]); however, these phase shifts will have some (albeit small) sensitivity to off-resonance effects over that range. In principle, ±600 Hz should be sufficient for AT alone, but it could be problematic if a chemical shift exists in the field gradients. This could explain the observed lower agreement, as measured by the CCC, between the *B*~1~-corrected VFA and IR *T*~1~ values in the AT. The potential off-resonance effects should not be considered a limitation to the Bloch--Siegert method, however, and can be compensated for using a map of the static magnetic field (ie, a B~0~ map).

There have been several recent studies investigating various *B*~1~ correction schemes for accurate *T*~1~ mapping of the breast at 3 T. Sung et al. ([@B35]) evaluated the accuracy of *T*~1~ measurements in the AT using the double-angle method of *B*~1~ mapping, which is a technique that uses the signal magnitude images at nominal flip angles α and 2α. Their results showed an average relative flip angle variation of 115% on the left breast and 82% on the right breast, which improved to 7% after *B*~1~ correction ([@B35]). Although the double-angle method generates robust measurements of *B*~1~ inhomogeneity, it is limited by its *T*~1~ dependence and the requirement for long TRs to mitigate the *T*~1~ dependence, which provides a possible barrier to clinical applications. The same group developed a technique to simultaneously map *B*~1~ and *T*~1~ using the AT as a reference region, and compared their results to the double-angle method ([@B17]). This technique uses a 2-point Dixon algorithm ([@B37]) to generate AT-only images and then assigns a known *T*~1~ value to a ratio of signal magnitudes to compute the *B*~1~ field variation. Sung et al. observed that the *B*~1~ maps generated with their postprocessing technique were similar to the double-angle method ([@B17]); therefore, they concluded that their approach, which is more time-efficient than the double-angle method, could be used to correct *B*~1~ inhomogeneities in breast MRI data.

Pineda et al. also developed a reference region technique to map the *B*~1~ transmit field using a population-average *T*~1~ value in the AT that was measured using an inversion recovery spectroscopic technique ([@B16]). These investigators evaluated their *B*~1~-mapping technique by comparing VFA-derived *T*~1~ values (before and after *B*~1~ correction) to IR *T*~1~ values in the breasts of 4 patients. Before correction, the absolute difference between VFA and IR values was 58% ± 21%, which was reduced to 8.1% ± 7.8% after the *B*~1~ correction ([@B16]). Although we observed similar results in our study, the Bloch--Siegert technique described herein is not limited by the necessary assumptions of a reference region technique, with the first assumption being that the *T*~1~ of AT in the breast is globally uniform and well characterized ([@B16], [@B17]). The second is the requirement for a large section of tissue in the FOV with a homogenous *T*~1~, which may not always be available in, for example, women with dense breasts ([@B17]). Another *B*~1~ mapping technique that may show promise in breast imaging is the DREAM approach by Nehrke and Bornert ([@B38]), which is a novel approach for robust, ultrafast, multislice *B*~1~ mapping.

The reproducibility analysis performed in this study provides objective statistical thresholds that define the range of repeatability by quantifying the maximum difference expected to be observed between 2 repeat measurements in an individual. In addition, the 95% CIs for the mean difference provide a measure of the spontaneous variability that is expected in a cohort of subjects. Both the 95% CIs of the mean difference and repeatability coefficient are useful when defining the associated variability in a measurement so that future studies can be designed and statistically powered appropriately. We observed lower 95% CIs of the mean difference and repeatability coefficients after *B*~1~ correction in all ROIs (including both breasts). We also observed an ∼50% reduction in the coefficient of variation between the repeated measures, thus suggesting lower variability after *B*~1~ correction. Therefore, our reproducibility analysis showed that the Bloch--Siegert *B*~1~ mapping technique improved reproducibility, thereby also improving precision, of VFA-derived *T*~1~ measurements in the breast at 3 T.

We attempted to be as consistent as possible when positioning each subject in the scanner and determining the imaging FOVs between repeated acquisitions. However, image registration between repeat acquisitions was not performed because the success of the registration results would be limited by the single-slice IR acquisition. We note that this is a limitation in the current study, as tests for accuracy and reproducibility were performed using only 1 slice. We would expect, however, that applying a longitudinal registration technique ([@B39]) would only improve accuracy and precision, as differences in subject position and imaging FOV would only minimally impact the results. In addition, by using the average *T*~1~ value from all of the AT and FGT voxels in the FOV, we felt that the accuracy and precision results would not be biased by a reader who, for example, would manually draw ROIs in the tissues. Another limitation to our study is the different number of data sets in the AT and FGT analyses. Our goal was to recruit a cohort of subjects with an age range that was representative of our ongoing clinical breast imaging study ([@B29]); however, some of the women included in this study had very little or no FGT because of either age or body habitus. We noted above that off-resonance effects could limit the accuracy of the Bloch--Siegert approach in areas of the breast where a chemical shift exists in the field gradients, which, for example, could be in the AT and areas of the breast with a mixture of AT and FGT. This limitation, however, would only affect the accuracy results described herein and should not be considered as a limitation of the Bloch--Siegert method, as chemical shift effects can be minimized by incorporating a map of the static magnetic field into the correction scheme.

Conclusion {#sec5}
==========

The VFA technique is often used in clinical applications of DCE-MRI, as it allows for 3D *T*~1~ mapping in a time-efficient manner. However, the accuracy of the technique is severely affected by inhomogeneities in the *B*~1~ transmit field, which are known to be significant in the breast at 3 T ([@B14]). The difference in the prescribed flip angle due to *B*~1~ inhomogeneities leads to inaccuracies in VFA-derived estimates of *T*~1~, which can compound to large errors in, for example, the DCE-MRI parameter *K^trans^* ([@B11], [@B36]). Large errors in DCE-MRI analyses could lower the sensitivity and specificity of the imaging technique, thereby limiting clinical adoption. Applying a *B*~1~ correction map is 1 technique, among others, that can be used to compensate for the inhomogeneities in the transmit field. In this study, we showed that *B*~1~ correction using the Bloch--Siegert shift is a viable (and attractive) option to measure accurate and precise VFA-derived *T*~1~ values in the breast at 3 T.
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